Compounds for the treatment of hepatitis C

A compound of formula I

• where:
• R1 is phenyl or pyridinyl and is substituted with 0-3 substituents selected from the group consisting of halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, hydroxyalkyloxy, and alkoxyalkyloxy, and is also substituted with 1 CON(R9)(R10) substituent;
• R2 is hydrogen, halo, or alkyl;
• R3 is CONHCH3;
• R4 is phenyl that is independently substituted with 0-2 halo or methoxy or is para substituted with X—Ar1;
• R5 and R6 are independently hydrogen, alkyl, halo, N(R7)(R8), or alkylsulfonyl;
• R7 and R8 are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, alkylsulfonyl, or alkylsulfonylalkyl;
• or N(R7)(R8) taken together is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, and is substituted with 0-2 substituents selected from alkyl, hydroxyalkyl, or hydroxy;
• R9 is hydrogen;
• R10 is
• R11 and R12 taken together is —CH2OCH2—, —OCH2CH2—, —CH2OCH2CH2—, —OCH2CH2CH2—, —OCH2CH2CH2CH2—, —CH2OCH2CH2CH2—, —CH2CH2OCH2CH2— (thus forming an oxetanyl, dihydrofuranyl, or dihydropyranyl ring);
• X is —O— or —NH—;
• Ar1 is phenyl or para-halophenyl;
• and
• Ar2 is phenyl, pyridinyl, pyrazolyl, isoxazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, oxadiathiazolyl, triazolyl, tetrazolyl, pyrazinyl, or pyrimidinyl, and is substituted with 0-3 substituents selected from halo, alkyl, or dialkylamino;
• or a pharmaceutically acceptable salt thereof.